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Abstract
Background: The present study coupled expression profiling with chromatin immunoprecipitation sequencing
(ChIP-seq) to examine peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)-dependent regulation of gene
expression in mouse keratinocytes, a cell type that expresses PPARβ/δ in high concentration.
Results: Microarray analysis elucidated eight different types of regulation that modulated PPARβ/δ-dependent
gene expression of 612 genes ranging from repression or activation without an exogenous ligand, repression or
activation with an exogenous ligand, or a combination of these effects. Bioinformatic analysis of ChIP-seq data
demonstrated promoter occupancy of PPARβ/δ for some of these genes, and also identified the presence of other
transcription factor binding sites in close proximity to PPARβ/δ bound to chromatin. For some types of regulation,
ATF4 is required for ligand-dependent induction of PPARβ/δ target genes.
Conclusions: PPARβ/δ regulates constitutive expression of genes in keratinocytes, thus suggesting the presence
of one or more endogenous ligands. The diversity in the types of gene regulation carried out by PPARβ/δ is
consistent with dynamic binding and interactions with chromatin and indicates the presence of complex regulatory
networks in cells expressing high levels of this nuclear receptor such as keratinocytes. Results from these studies
are the first to demonstrate that differences in DNA binding of other transcription factors can directly influence
the transcriptional activity of PPARβ/δ.
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Background
Peroxisome proliferator-activated receptor-β/δ (PPARβ/
δ) is a ligand activated transcription factor with particu-
larly high abundance in small intestine, colon, liver, and
skin [1-4]. In these tissues, PPARβ/δ likely has a consti-
tutive physiological role, possibly modulated by the pres-
ence of an endogenous ligand. This is consistent with
the fact that PPARβ/δ is required to mediate the induc-
tion of terminal differentiation in epithelial cells [5-10].
PPARβ/δ also attenuates inflammation and regulates
glucose and lipid homeostasis [5-11]. These important
physiological roles underscore the potential for targeting
PPARβ/δ for the prevention and/or treatment of diverse
diseases, including cancer, diabetes, metabolic syndrome,
and dyslipidemias [5-10,12].
PPARβ/δ modulates cellular function by regulating
gene expression through several mechanisms. For ex-
ample, PPARβ/δ can interact and bind with other tran-
scription factors, including NFκB, ERK5, and STAT3,
and attenuate their signaling [5-10]. PPARβ/δ can also
repress gene expression by dynamically binding to chro-
matin in association with co-repressors [13,14]. The
most commonly described mechanism by which PPARβ/
δ was thought to regulate gene expression is that bind-
ing of ligand to receptor induces a conformational
change in the protein. This change in structure is
accompanied by the release of co-repressors, heterodimer-
ization with the retinoid X receptor (RXR), recruitment of
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co-activators and RNA polymerase II and increased tran-
scription when this complex is bound to peroxisome
proliferator response elements (PPREs) proximal to tar-
get genes. However, more recent studies indicate that
nuclear receptors actually regulate gene expression
through dynamic and sometimes transient interactions
with chromatin rather than through static complexes
occupying chromatin [15-18]. This suggests that the
dynamic and transient occupancy of PPARβ/δ on chro-
matin must be considered when attempting to interpret
receptor-DNA binding studies [15-18]. There are many
different classes of enzymes that can modify nucleosome
location and/or chromatin structure that will allow for
nuclear receptors to dynamically and transiently bind to
chromatin, and this binding can be markedly changed in
response to the presence of endogenous and exogenous
ligands [15-18]. Further, there is evidence that the dy-
namic interactions between agonist-activated nuclear
receptors with their co-regulators and DNA binding sites
can lead to highly variable responses including differ-
ences in: 1) the regions of chromatin occupied by the re-
ceptor, 2) expression of target genes and 3) the ultimate
biological effect. Conformational changes in a receptor
caused by different agonists, antagonists and partial ago-
nists can cause differential recruitment of co-regulators
resulting in alteration of the dynamics of transcriptional
complexes and interactions with DNA binding sites.
Thus, there are multiple levels of regulation by which
PPARβ/δ can influence the expression of target genes.
Characterization of bona fide target genes directly
regulated by PPARβ/δ in all tissues is incomplete.
Angiopoietin-like 4 (Angptl4) and adipocyte differentiation-
related protein (Adrp) are two genes that can be modu-
lated by PPARβ/δ by direct transcriptional regulation.
That Angptl4 and Adrp are direct target genes is based
on analyses demonstrating: 1) that functional PPREs exist
proximal to these genes, and 2) confirmed promoter
occupancy of PPARβ/δ following ligand activation [19-21].
In addition to these experimentally confirmed PPARβ/δ
target genes, in silico screening based on genomic PPRE
frequency predicted as many as 4000 to 5000 targets for
PPARs in the human genome [22-24] and a compar-
able number of binding sites for PPARs in some cells
have been confirmed by chromatin immunoprecipitation
sequencing (ChIP-seq) [25]. This suggests that many
PPARβ/δ binding sites and target genes remain unidenti-
fied. Moreover, recent studies have used next genera-
tion sequencing to elucidate novel regulatory roles for
PPARβ/δ. For example, ChIP-seq was used to demon-
strate that PPARβ/δ and PPARγ can be exchanged on
target gene in adipocytes, following ligand activation of
PPARγ [26]. Thus, the present studies were designed to
examine novel regulation of PPARβ/δ-dependent gene
transcription in keratinocytes.
Results
PPARβ/δ-dependent regulation of genes in keratinocytes
Six hundred and twelve genes were identified by
genome-wide expression profiling that were differentially
regulated by either ligand, disruption of PPARβ/δ, or
both (Figure 1A, Table 1, Additional file 1: Table S2).
These genes were categorized into four major response
types: (I) repression without exogenous ligand (n=185),
(II) activation without exogenous ligand (n=297), (III)
activation with exogenous ligand (n=71), and (IV)
repression with exogenous ligand (n=28). qPCR con-
firmed these four common types of PPARβ/δ-dependent
changes in gene expression detected by microarray ana-
lysis (Figure 2). Combined, these comprised 94.9% of the
genes identified that were differentially regulated by ei-
ther ligand, disruption of PPARβ/δ, or both. An add-
itional four response types exhibiting combined
responses were also observed: (V) repression without
exogenous ligand and activation with exogenous ligand
(n=12), (VI) activation without exogenous ligand and
repression with exogenous ligand (n=9), (VII) activation
with and without exogenous ligand (n=1), and (VIII)
repression with and without exogenous ligand (n=9)
(Figure 1A, Table 1). The latter four response types only
comprised ~5% of the genes modulated by GW0742
and/or disruption of PPARβ/δ.
Characterization of the PPARβ/δ target genes and
their transcriptional responses was undertaken by func-
tional category enrichment analysis [27,28]. 50% of the
enriched functional categories were common between
type I and type II responses (Figure 1B). Genes that
regulate fatty acid metabolism were common between
type III and type V responses (Figure 1B). The level of
gene expression observed following ligand activation was
compared to changes in gene expression observed by
disruption of PPARβ/δ (Figure 1C). This analysis
revealed clustering for the eight different response types,
but there were differences in the magnitude of change
found for each of the response types (Figure 1C). The
conventional view accounting for combined responses
involving activation/repression in both the presence and
absence of exogenous ligand (types V and VI, e.g.
Lpcat3) suggests that a ligand-mediated switch occurs
between repression and activation (type V) or vice-versa
(type VI) [13]. For example, in the absence of PPARβ/δ,
expression of Lpcat3 is enhanced because PPARβ/δ
represses expression, whereas ligand activation of PPARβ/δ
increases expression of Lpcat3. This phenomenon was
also observed with type VI genes, consistent with a ligand-
mediated release of an activating complex. However, it is
important to point out that the level of ligand-dependent
expression typically exhibited in type V genes was of gen-
erally greater magnitude (average 1.6 fold) as compared to
the level of expression observed when PPARβ/δ was
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disrupted, but this effect was not found for type VI
responses (Figure 1D). This suggests that ligand and
receptor-dependent regulation of gene expression can be
mediated by distinctly different mechanisms, even for a
single gene.
Genome-wide characterization of PPARβ/δ occupancy on
chromatin
ChIP-seq was performed to examine the molecular
mechanisms by which PPARβ/δ regulates gene expression.
To accomplish this, a ChIP-grade antibody is required. A
polyclonal anti-PPARβ/δ antibody [2] was ~94X more effi-
cient for immunoprecipitation of vitro translated PPARβ/δ
as compared to one commercially available anti-PPARβ/δ
antibody [2]. Further, this antibody was effective for
demonstrating increased promoter occupancy of PPARβ/δ
on the Angptl4 promoter in mouse keratinocytes
following ligand activation of PPARβ/δ (Figure 3A) and
was used for ChIP-seq to identify PPARβ/δ cistromes in
keratinocytes. Between 17,575,718 and 27,509,922 reads
per sample were obtained by ChIP-seq and more than
98% of these reads were retained after quality control. Of
these reads, between 66 and 73% were successfully
mapped to the mouse genome for the control and
GW0742-treated samples (Table 2).
Bioinformatic analysis of ChIP-seq data revealed occu-
pancy of PPARβ/δ on 6,839 sites in chromatin from con-
trol cells (binding without exogenous ligand) and 15,882
sites in chromatin from GW0742 treated cells (binding
with exogenous ligand); their absence in equivalent
Figure 1 Eight distinctly different PPARβ/δ-dependent mechanisms of transcriptional regulation. (A) 612 genes were categorized into
eight different response types. Relative expression was based by comparison with control, wild-type mouse keratinocytes. White indicates basal
expression; red indicates higher expression compared to control, wild-type mouse keratinocytes; green indicates lower expression compared to
control, wild-type mouse keratinocytes. An up arrow indicates repression and a down arrow indicates activation. The number of genes within
each category is shown in the bar graph. (B) Enrichment of functional gene categories of the 612 differentially regulated genes within each of
the response types. Statistically significant enriched gene categories were identified by PANTHER (P ≤ 0.05) and are indicated by a box, with
darker shaded boxes depicting lower P values. (C) Comparison of gene expression profiles observed with disruption of PPARβ/δ (y axis) and
activation with GW0742 in wild-type keratinocytes (x axis) for the 612 genes as categorized by response type. Relative gene expression levels
were log transformed and a ratio relative to control wild-type keratinocytes was plotted for each gene. (D) Violin plots of the log transformed
ratios of gene expression in wild-type keratinocytes treated with GW0742 compared to Pparβ/δ−/− keratinocytes for the type V and VI responses.
Each data point represents the mean of at least three independent biological replicates. The mean ratio is shown next to each violin plot.
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Pparβ/δ-null cells confirmed specificity (Figure 4A). The
region of DNA amplified by ChIP qPCR showing
increased promoter occupancy of PPARβ/δ on the
Angptl4 gene following ligand activation (Figure 3A) was
also associated with significant occupancy of PPARβ/δ
based on ChIP-seq analysis (Figure 3B) confirming spe-
cificity of promoter occupancy detected by ChIP-seq.
Annotation of the genomic features associated with the
identified peaks revealed unique patterns of PPARβ/δ
occupancy on specific chromosomes (Figure 3B). As
compared to the percentage of bases in the entire mouse
genome per chromosome, the percentage of peaks iden-
tified by ChIP-seq that were associated with PPARβ/δ
binding was significantly greater on chromosomes 7, 9,
11 and 17 and significantly less on chromosomes 1, 3,
13, 18 and X in control, wild-type keratinocytes
(Figure 4B). As compared to the percentage of bases in
the entire mouse genome per chromosome, the percent-
age of peaks identified by ChIP-seq that were associated
with PPARβ/δ binding was significantly greater on chro-
mosomes 2, 4, 15 and 19 and significantly less on chro-
mosomes 8, 12 and 14 following ligand activation of
PPARβ/δ (Figure 4B). Annotation of the genomic fea-
tures associated with the identified peaks also revealed
that the majority of PPARβ/δ binding to chromatin is
found at intronic sites (43.8 – 47.9%), with significant
enrichment also observed in the upstream (9.3 – 20.1%)
and downstream (2.5 – 6.7%) regions from the TSS;
which varied depending on the distance upstream from
the transcriptional start site (TSS); Figures 4C, 4D).
However, as compared to the percentage of bases in the
entire mouse genome that represents intronic sequences
(39.8%), the percentage of peaks identified by ChIP-seq
that were associated with PPARβ/δ binding (43.8 –
47.9%) was not strikingly different (Figure 4D). In con-
trast, as compared to the percentage of bases in the
entire mouse genome that are in relatively close proxim-
ity to the TSS (≤ 2.7%), the percentage of peaks identi-
fied by ChIP-seq that were associated with PPARβ/δ
binding (9.3 – 20.1%) was between 3- and 7-fold higher
(Figure 4C).
Integrative analysis of the PPARβ/δ transcriptome
and cistrome
Binding regions were assigned gene names according to
the nearest TSS. As transcription factors may regulate
genes at distal loci (e.g. > 30 kb), a high-confidence
binding site and direct target gene set was obtained by
identifying genes exhibiting both PPARβ/δ occupancy
within ± 10 kB of the gene, and PPARβ/δ-dependent dif-
ferential expression as revealed by microarray analysis
(Figures 4A, 5A). 79 genes were identified that exhibited
PPARβ/δ occupancy on chromatin without exogenous
ligand and exhibited PPARβ/δ-dependent differential
expression (Figure 4A). Further, 150 genes were identified
that exhibited PPARβ/δ occupancy on chromatin with
exogenous ligand and exhibited PPARβ/δ-dependent
differential expression (Figure 4A). Twenty-six of these
genes exhibited PPARβ/δ occupancy on chromatin with
and without exogenous ligand and exhibited PPARβ/δ-
dependent differential expression (Figure 4A). This inte-
grated, high-confidence “direct target gene set” and
“binding region set” was utilized for analyses of PPARβ/
δ-chromatin interactions (Figure 5).
Of the 612 PPARβ/δ-dependent differentially regulated
genes detected with the microarray analysis, 203 (33%)
of these genes also displayed PPARβ/δ occupancy within
10 kb of the TSS (Additional file 2: Table S3). Fifty-seven
of the 203 direct target genes exhibited a type I response
and promoter occupancy of PPARβ/δ was found in 23
(40%) of these genes within 10 kb of the TSS in the ab-
sence of exogenous ligand (Figures 5A, 5B). Interest-
ingly, in 34 of these genes, PPARβ/δ occupancy was
only detected in the presence of exogenous ligand
(Figures 5A, 5B). Of the 93 direct PPARβ/δ genes exhi-
biting a type II response, promoter occupancy of
PPARβ/δ was found in 37 (40%) of these genes within
10 kb of the TSS in the absence of exogenous ligand
(Figures 5A, 5B) but in 56 of these genes, PPARβ/δ
occupancy was only detected in the presence of exogen-
ous ligand (Figures 5A, 5B). The occupancy of PPARβ/δ
within 10 kb of the TSS found with and without exogen-
ous ligand was relatively equally distributed with more
predominant occupancy near the TSS for both type I
Table 1 Types of transcriptional responses observed
following ligand activation of PPARβ/δ in mouse primary
keratinocytes
Type Without exogenous ligand With exogenous ligand
I Repression –
II Activation –
III – Activation
IV – Repression
V Repression Activation
VI Activation Repression
VII Activation Activation
VIII Repression Repression
The effect without exogenous ligand reflects the response in expression of a
particular gene observed in control Pparβ/δ-null keratinocytes as compared to
control wild-type keratinocytes. For this column, repression indicates that gene
expression is higher in Pparβ/δ-null cells as compared to wild-type cells and
activation indicates that gene expression is lower in Pparβ/δ-null cells as
compared to wild-type cells. The effect with exogenous ligand reflects the
response in expression of a particular gene observed in wild-type
keratinocytes treated with the highly specific PPARβ/δ ligand GW0742 as
compared to control wild-type keratinocytes. For this column, activation
indicates that gene expression is higher in GW0742-treated wild-type cells as
compared to control wild-type cells and repression indicates that gene
expression is lower in GW0742-treated wild-type cells as compared to control
wild-type cells.
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and type II response genes (Figure 5C). Thirty-one of
the 203 direct target genes exhibited a type III response
and promoter occupancy of PPARβ/δ within 10 kb of
the TSS was found for all of these genes but was found
in the absence and/or presence of exogenous ligand
(Figures 5A, 5B). For type III response genes, occupancy
of PPARβ/δ without exogenous ligand occurred more
predominantly near the TSS with some skewness in the
region downstream of the TSS (Figure 5C). In the pres-
ence of exogenous ligand, the occupancy of PPARβ/δ
observed for type III response genes was predominant
near the TSS but there was a shift in binding towards
the region upstream of the TSS compared to the occu-
pancy of PPARβ/δ observed without exogenous ligand
(Figure 5C). Of the 12 direct PPARβ/δ genes that exhib-
ited a type IV response, promoter occupancy of PPARβ/
δ within 10 kb of the TSS was found for all of these
genes in the absence and/or presence of exogenous
ligand (Figures 5A, 5B). For type IV response genes, in
the absence of exogenous ligand occupancy of PPARβ/δ
was near the TSS with a cluster of binding in the region
upstream of the TSS and some skewness in the region
downstream of the TSS (Figure 4C). The occupancy of
PPARβ/δ observed for type IV response genes in the
presence of exogenous ligand was shifted towards the re-
gion upstream of the TSS compared to the occupancy of
PPARβ/δ observed without exogenous ligand (Figure 5C).
Four of the 203 direct target genes exhibited a type V
response and promoter occupancy of PPARβ/δ within
10 kb of the TSS was found for all of these genes in the
absence and/or presence of exogenous ligand (Figures 5A,
5B). Of the 3 direct PPARβ/δ genes that exhibited a type
VI response, promoter occupancy of PPARβ/δ within
10 kb of the TSS was found for all of these genes in the
absence and/or presence of exogenous ligand (Figures 5A,
5B). The single type VII response gene detected by micro-
array analysis did not exhibit occupancy of PPARβ/δ
based on this analysis. Three of the 203 direct target
genes exhibited a type VIII response and promoter occu-
pancy of PPARβ/δ within 10 kb of the TSS was found
for all of these genes in the absence and/or presence of
exogenous ligand (Figures 5A, 5B). ChIP-qPCR was
Figure 2 qPCR confirmation of PPARβ/δ-dependent changes in gene expression detected by microarray analysis. (A) qPCR analysis
of the four most common types of regulation (I-IV) was examined using RNA from control and GW0742-treated wild-type (Pparβ/δ+/+) and
Pparβ/δ-null (Pparβ/δ−/−) keratinocytes. *Significantly different than control, P ≤ 0.05 as determined by ANOVA and post-hoc testing.
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performed for representative genes from the four major
response types to confirm PPARβ/δ occupancy and chro-
matin modifications (Figure 6).
Unique DNA binding motifs near sites of PPARβ/δ
occupancy on chromatin
A consensus PPRE motif for PPARβ/δ was generated
using a list of 53 validated PPRE consensus sequences
obtained from the literature [29] using STAMP [30]
(Figure 7). This sequence was used to search for matches
in the ChIP-seq peaks in both control and GW0742-
treated samples. The consensus PPRE motif identified
from this analysis was GGGNCAAAGGTCA (Figure 7).
The RXR half-site was conserved whereas the PPARβ/δ
half-site showed some variation as compared to the con-
sensus PPRE motif based on the published literature
(Figure 7). Consensus binding sites for a number of
other transcription factors were also found in proximity
to regions where PPARβ/δ occupancy was noted
(Figure 8A). For example, in control chromatin from
wild-type keratinocytes not treated with an exogenous
ligand, a high percentage (73.3 – 98.1%) of consensus
Figure 3 Characterization of ChIP-grade anti-PPARβ/δ antibody. (A) ChIP analysis for AcH4 or PPARβ/δ occupancy on chromatin from
wild-type or Pparβ/δ-null keratinocytes treated with or without GW0742 (0.2 μM). qPCR was performed using chromatin immunoprecipitated
with either an anti-AcH4 or the 8099 anti-PPARβ/δ antibody. (B) Integrated overview of microarray expression and ChIP-seq data for Angptl4.
The region of the Angptl4 gene is shown in red on chromosome 17, and the corresponding genomic location of this gene is depicted below.
Relative expression of Angptl4 is shown for the four treatment groups (wild-type and Pparβ/δ-null, with and without GW0742) with white
representing basal expression, red representing greatly enhanced expression and pink representing enhanced expression. The exonic and intronic
organization of the Angptl4 gene is depicted with boxes (exons) and lines (introns). Regions associated with increased PPARβ/δ occupancy based
on ChiP-seq analysis (peaks) are shown in boxes corresponding to the genomic regions depicted above with the Z score listed below. Note the
intronic region used for ChIP in (A), which is highlighted by arrows, is associated with a peak detected by ChIP-seq.
Table 2 ChIP-seq reads of DNA from wild-type (Pparβ/δ+/+) and Pparβ/δ-null (Pparβ/δ−/−) keratinocytes
Pparβ/δ+/+ Pparβ/δ−/−
Input DMSO GW0742 Input DMSO GW0742
Reads (Run 1) 6173615 11774655 17489428 13397018 9111547 10955382
Reads (Run 2) 11402103 9298650 10020494 13963586 11731976 11870020
Total Reads 17575718 21073305 27509922 27360604 20843523 22825402
Quality Control Passed Reads 17521514 20910231 27379614 27247515 20625001 22363483
% QC Passed 99.69 99.23 99.53 99.59 98.95 97.98
Mapped Reads 16016425 15351905 19552539 25239456 14630180 14770720
% Mapped 91.41 73.42 71.41 92.63 70.93 66.05
The number of reads per sample is shown for each of two runs, along with the total number of reads obtained for bioinformatic analysis. The percentage of total
reads that passed quality control as described in Materials and Methods (% QC Passed) and the number (Mapped Reads) and percentage of reads that were
successfully mapped to the mouse genome (% Mapped) are shown.
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binding sites for ELF4, ELK3, ETV3 and PAX4 were also
found in ChIP-seq peaks (Figure 8A). Additionally, in
chromatin from wild-type keratinocytes treated with
GW0742, a high percentage (63.3 – 83.8%) of consensus
binding sites for ATF4, E4F1, ERG, NR1H4, and ZFP691
were also found in ChIP-seq peaks (Figure 8A).
Differences in the presence of consensus binding sites
for a number of transcription factors were also found in
regions where PPARβ/δ occupancy was noted between
response types (Figure 8A). For genes exhibiting a type I
response, a high percentage (78.5 – 98.9%) of consensus
binding sites for MYCN, NR1H2:RXR, and RFX3 were
Figure 4 Characterization of PPARβ/δ binding on chromatin in keratinocytes. (A) ChIP-seq analysis was performed to identify regions
of chromatin with PPARβ/δ occupancy (Hotspot analysis). These data were filtered to correct for background by removing peaks detected in
Pparβ/δ-null samples and to identify peaks within a ± 10 kb region of any transcription start site (TSS). These filtered data were then compared
with expression levels of genes to identify direct PPARβ/δ target genes that were regulated with and without exogenous ligand (B) Annotation
of ChIP-seq peaks with chromosome localization. The percentage of the mouse genome on each chromosome is shown in relationship to
the percentage of the ChIP-seq peaks detected that were localized to each chromosome. (C) Annotation of ChIP-seq peaks either upstream or
downstream from TSS. The percentage of the ChIP-seq peaks detected that were localized between 1000 and 3000 bp from the TSS is shown
as compared to the percentage of the mouse genome in these regions. (D) Annotation of ChIP-seq peaks in the intragenic 50-UTR, 30-UTR,
coding exons and introns. The percentage of the ChIP-seq peaks detected in intragenic 50-UTR, 30-UTR, coding exons and introns is shown as
compared to the percentage of the mouse genome in these regions. *Significantly different from respective genomic control, P ≤ 0.05 as
determined by ANOVA and post-hoc testing.
Khozoie et al. BMC Genomics 2012, 13:665 Page 7 of 19
http://www.biomedcentral.com/1471-2164/13/665
Figure 5 (See legend on next page.)
Khozoie et al. BMC Genomics 2012, 13:665 Page 8 of 19
http://www.biomedcentral.com/1471-2164/13/665
also found in ChIP-seq peaks in chromatin from wild-
type keratinocytes (Figure 8A). A high percentage (68.8
– 90.1%) of consensus binding sites for ELK3, ELK4,
ERG, TS1, FLI1, and GM5454 were also found in ChIP-
seq peaks in chromatin from wild-type keratinocytes for
genes exhibiting a type II response (Figure 8A). For
genes exhibiting a type III response, a high percentage
(71.7 – 95.7%) of consensus binding sites for ATF4,
DUXBL, E4F1, MECP2, and ZNF423 were also found in
ChIP-seq peaks in chromatin from wild-type keratino-
cytes (Figure 8A). Related transcription factors were
grouped by phylogenic analysis revealing two major fam-
ilies of transcription factor binding sites, ETS and
CREB/ATF/AP1, that were associated near regions
where PPARβ/δ was found to occupy (Figure 8B). Inter-
estingly, binding sites for the ETS family of transcription
factors were found near regions of chromatin occupied
by PPARβ/δ in either the presence or absence of exogen-
ous ligand, whereas binding sites for the CREB/ATF/AP1
family of transcription factors were more commonly
found in regions of chromatin occupied by PPARβ/δ
only in the presence of ligand (Figure 8B). No significant
enrichment of consensus binding sites for other tran-
scription factors were found in ChIP-seq peaks from the
type IV-VIII response genes.
Co-regulation of PPARβ/δ target genes by ATF4
Because ATF4 binding motifs were commonly observed
proximal to PPARβ/δ binding regions, ChIP assays were
performed to confirm that both transcription factors oc-
cupied these regions of DNA. Interestingly, for three
type III response genes (Adrp, Prickle1 and Snai3) and
one type V gene (Angptl4), ligand activation of PPARβ/δ
was associated with an increase in promoter occupancy
of both PPARβ/δ and ATF4 (Figure 9A). This effect was
not observed in Pparβ/δ-null cells. Because effective
knockdown of ATF4 could not be achieved in primary
keratinocytes, the SP1 keratinocyte cell line [31] was
used to examine the effect of ATF4 knockdown. Of the
three ATF4 shRNA vectors used, effective knockdown of
(See figure on previous page.)
Figure 5 Characterization of different response types by integration of cistromic and genome-wide expression profiling analysis.
(A) Comparison of PPARβ/δ occupancy of the 203 direct target genes between the different response types. PPARβ/δ occupancy is shown
without (blue dots) and with (red dots) exogenous ligand (GW0742) in relation to the TSS. Relative expression of the target genes in wild-type
(+/+) and Pparβ/δ-null (−/−) samples is shown in the heat map to the right of this analysis. (B) Relative distribution of PPARβ/δ occupancy in the
absence or presence of exogenous ligand for the different response types. (C) The distribution of PPARβ/δ occupancy in relation to the TSS for
the direct target genes for the four major response types.
Figure 6 ChiP-qPCR validation of PPARβ/δ occupancy for the four major response types. Chromatin from keratinocytes was used for ChIP
and the immunoprecipitated chromatin used for qPCR of regions where PPARβ/δ occupancy was detected by ChIP-seq for one representative
gene of each major response type.
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ATF4 was achieved with two of the vectors (Figure 9B).
Interestingly, when ATF4 was knocked down, the rela-
tive increase in gene expression of the type III genes
Adrp, Prickle1, and Snai3 observed following ligand acti-
vation of PPARβ/δ was reduced (Figure 9C). Addition-
ally, the relative increase in gene expression of the type
V gene Angptl4 observed following ligand activation of
PPARβ/δ was also markedly reduced when ATF4 was
knocked down (Figure 9C).
Discussion
Results from the present study are the first to demon-
strate genome-wide changes in gene expression mediated
specifically by PPARβ/δ in mouse keratinocytes. Kerati-
nocytes provide an outstanding model to examine gene
expression mediated by PPARβ/δ because of the consti-
tutively high expression of the receptor [2]. Comparison
of wild-type and Pparβ/δ-null keratinocytes revealed
that PPARβ/δ constitutively regulates expression of 482
genes. Further, activation of PPARβ/δ altered expression
of 99 genes that required PPARβ/δ. The ultimate pheno-
type resulting from ligand activation of PPARβ/δ in kera-
tinocytes cannot be determined based solely on the gene
expression profiles obtained from these studies but they
are consistent with previous studies showing that activat-
ing PPARβ/δ in keratinocytes and/or skin promotes ter-
minal differentiation, inhibits cell proliferation, improves
barrier function and inhibits inflammation [11,32-35].
Thus, it is also worth noting that activating PPARβ/δ can
induce terminal differentiation and modulate lipid me-
tabolism in keratinocytes coincident with changes in the
regulation of target genes observed in these studies, con-
sistent with previous work [32,36,37]. Expression of
Pdpk1, Ilk, or Pten was not altered by ligand activation
of PPARβ/δ in the present studies, which is also in line
with a previous study [38], but in contrast to another
study [39]. Increased expression of Hb-Egf and many
pro-inflammatory genes was also reported in human ker-
atinocytes and skin of transgenic mice over-expressing
human PPARβ/δ, respectively, following activation with
a PPARβ/δ ligand [40,41]. However, changes in expres-
sion of these genes were not observed in the present
studies. Further work is needed to determine the reason
for these inconsistencies.
Genes were categorized into eight distinct response
types representing essentially every combination of tran-
scriptional activation and/or repression in response to
exogenous ligand and/or PPARβ/δ disruption. Interest-
ingly, the type I and II responses that occur independent
of exogenous ligand were the most commonly observed
(79%). There are two existing models that could explain
this regulation. First, PPARβ/δ can dynamically occupy
chromatin in association with co-repressors leading to
repression of gene expression [14]. This model explains
why type I genes are induced in Pparβ/δ-null keratino-
cytes in the absence of exogenous ligand. Whether
an endogenous ligand(s) is part of this complex remains
uncertain. ChIP-seq analysis confirmed promoter occu-
pancy of PPARβ/δ in some genes exhibiting a type I
response. The second model is that the PPARβ/δ-RXR
heterodimer in association with co-activators and RNA
polymerase II is dynamically binding chromatin as a
result of the presence of an endogenous ligand or
ligands, and available chromatin binding sites as a result
of the activities of DNA modifying enzymes [15-18].
Thus, when PPARβ/δ is disrupted, the expression of
these type II genes is reduced. This is in agreement with
the promoter occupancy of PPARβ/δ detected by ChIP-
seq for some genes exhibiting a type II response. The
fact that occupancy of PPARβ/δ was not detected for all
of the type I and II genes is likely due to: 1) the dynamic
fluid nature of PPARβ/δ binding with chromatin, which
has multiple levels of regulation, 2) the fact that PPREs
for these genes could exist in chromatin at distant sites
not in close proximity to the TSS [15-18], or 3) local
chromatin status at some PPREs may preclude binding
at those sites [18]. Of the functional categories of genes
that exhibited type I or II responses, approximately 50%
of these categories were altered by both response types,
suggesting common factors that induce these changes
are somewhat independent of the direction of the regu-
lation observed (e.g. repression or activation).
Type III and IV responses that were dependent on ex-
ogenous ligand activation, were the next most common
type of gene regulation observed (16%). These responses
were characterized by a lack of constitutive regulation by
PPARβ/δ, but regulatory changes arising after treatment
with exogenous ligand. Type III responses are consistent
with dynamic nuclear receptor-mediated up-regulation
of target gene expression [15-18]. Indeed, less promoter
Figure 7 Consensus PPRE sequence identified by binding site
analysis. A consensus PPRE motif for PPARβ/δ was determined
using a list of 53 validated PPRE consensus sequences obtained
from the literature. These data were used for comparison with DNA
sequences where PPARβ/δ occupancy was detected by ChIP-seq
to reveal the most consistent PPRE motif.
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Figure 8 (See legend on next page.)
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occupancy of PPARβ/δ was found in the absence of
exogenous ligand and increased promoter occupancy of
PPARβ/δ was noted following ligand activation. It is
curious to note that expression of type II target genes
was not increased by an exogenous ligand, since it
appears that constitutive expression of type II genes is
driven by an endogenous ligand(s). In contrast, constitu-
tive expression of type III response genes did not appear
to be altered by an endogenous ligand, and was only
increased by an exogenous ligand. There are at least two
mechanisms that could explain these differences. First,
the presence of an endogenous ligand in relatively high
concentration (or at sufficient concentration to saturate
the receptor) that also exhibits higher affinity for
PPARβ/δ as compared to GW0742 could explain why an
exogenous ligand does not further increase expression of
a type II response gene. This would suggest that there
are different endogenous ligands that cause differential
conformational changes in the receptor following ligand
activation and/or differences in the recruitment of co-
effector proteins to the complex to modulate specific
subsets of PPARβ/δ target genes. Alternatively, the con-
centration of an exogenous ligand could be greater than
an endogenous ligand and sufficient to activate the
receptor, and/or have higher affinity for PPARβ/δ than
an endogenous ligand (e.g. the endogenous ligand is in
low concentration and unable to activate PPARβ/δ and/
or the endogenous ligand has low affinity). This scenario
also implies that the ligand could uniquely alter receptor
conformation and/or recruitment of co-effector proteins
to the transcriptional complex as compared to that
which occurs in response to an endogenous ligand. The
data from the present studies also indicate that PPARβ/δ
does not influence expression of type IV genes in the
absence of exogenous ligand, but that ligand activation
causes recruitment of PPARβ/δ to regions near the TSS
and this increase in occupancy is associated with repres-
sion of gene expression for 28 genes. Whereas repres-
sion of gene expression observed for type I response
genes could be mediated by dynamic occupancy of
PPARβ/δ in the absence of exogenous ligands in com-
plex with co-repressors as suggested by other studies
[14], the precise mechanism that underlies this exogen-
ous ligand-dependent effect is uncertain and requires
further studies. In general, there was a lack of overlap
between the functional categories of regulatory pathways
modulated by type I/II as compared to type III/IV
response genes. This supports the view that PPARβ/δ is
integrated into distinct transcriptional response path-
ways mediated by distinct mechanisms that may be
influenced by more than one endogenous ligand. The
fact that PPARβ/δ has a relatively large ligand binding
domain as compared to other PPARs [42] and nuclear
receptors supports the idea that PPARβ/δ can accommo-
date more than one endogenous ligand. Moreover, this
analysis also suggested that PPARβ/δ can tightly bind
more than one type of fatty acid, a feature that interfered
with solving the crystal structure of the ligand binding
domain [43], consistent with the hypothesis that more
than one endogenous ligand exists for PPARβ/δ.
Mixed responses were observed for a much smaller
cohort of PPARβ/δ target genes (5%). Type V response
genes exhibited responses that were similar to those
found with type I and III genes because in the absence
of exogenous ligand and PPARβ/δ, expression was
higher yet ligand activation of PPARβ/δ caused an
increase in expression. Conversely, type VI response
genes exhibited responses that were similar to those
found with type II and IV genes because in the absence
of exogenous ligand and PPARβ/δ, expression was lower
and ligand activation of PPARβ/δ caused a decrease in
expression. One mechanism that explains these response
types is that a ligand-mediated switch occurs between
repression and activation (type V) or vice-versa (type VI)
[13]. For example, when PPARβ/δ is disrupted, expres-
sion of Angptl4 is enhanced because PPARβ/δ represses
expression, whereas ligand activation of PPARβ/δ
increases expression of Angptl4. This phenomenon was
inversed but also observed with type VI genes, consistent
with a ligand-mediated release of an activating complex.
However, it is important to point out that constitutive
expression Angptl4 and other type V response genes
were typically much lower than the levels observed fol-
lowing activation by an exogenous ligand. This is con-
sistent with a model where PPARβ/δ represses without
an endogenous ligand and that binding of ligand to
the receptor causes recruitment of transcriptional pro-
teins and increased transcription after forming a tran-
scriptional complex that increases transcription and/or
outcompetes the repressive complex for repression.
Alternatively, an exogenous ligand could alter the ratio
of repressive PPARβ/δ complexes to activated PPARβ/δ
(See figure on previous page.)
Figure 8 Transcription factor DNA binding motifs proximal to PPARβ/δ binding regions. (A) Enrichment of transcription factor binding
motifs proximal to PPARβ/δ binding regions observed in the absence (DMSO) or presence (GW0742) of exogenous ligand, or with the different
response types (I-III) are shown. Values represent the percentage of binding regions containing the indicated transcription factor DNA binding
motif. The indicated consensus transcription factor DNA binding motifs are also shown. (B) Sequence similarities between the transcription factor
DNA binding motifs were identified by multiple sequence alignments and are shown in a phylogenetic tree. The parentheses indicate the two
most common families observed (CREB/ATF/AP1 and ETS).
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Figure 9 PPARβ/δ and ATF4 co-operatively modulate gene expression. (A) ChIP assays demonstrating promoter occupancy of both
PPARβ/δ and ATF4 on representative type III target genes (Adrp, Prickle1 and Snai3) and one type V target gene (Angptl4). (B) Knockdown of
ATF4 in SP1 cells. Upper panel shows mRNA analysis demonstrating effective knockdown of ATF4 by two of three shRNA vectors compared to
control. Lower panel shows western blot analysis confirming ATF4 knockdown. (C) Effect of ATF4 knockdown on ligand activation of PPARβ/δ in
SP1 cells. qPCR analysis of representative type III target genes (Adrp, Prickle1 and Snai3) and one type V target gene (Angptl4). Values represent
the mean ± S.E.M.. *Significantly lower ligand induction as compared to control as determined by ANOVA and post-hoc testing.
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complexes limiting the availability of PPARβ/δ to form
repressive complexes on chromatin. Results from the
analysis of type V genes in the present studies is in con-
trast to previous work by others showing comparable
levels of expression of genes following either PPARβ/δ
knockdown or activation by an exogenous ligand in
human WPMY1 myofibroblast cells [13], for genes exhi-
biting similar regulation as observed in the present stud-
ies. This could reflect differences in: 1) the
concentration of available ligand, 2) chromatin structure
near the Angptl4 gene, and/or 3) co-effector proteins
recruited to alter chromatin structure. The single type
VII response gene exhibited a response that was similar
to that found with type II and III genes because in the
absence of exogenous ligand and PPARβ/δ, expression
was modestly lower and ligand activation of PPARβ/δ
with GW0742 caused an increase in expression. The
type VII response is consistent with a model whereby an
endogenous ligand drives constitutive expression and
an exogenous ligand increases this expression through
mechanisms described above for type II and III response
types. In contrast, type VIII response genes exhibited a
response that was similar to those found with type I and
IV genes because in the absence of exogenous ligand
and PPARβ/δ, expression was modestly higher and lig-
and activation of PPARβ/δ with GW0742 caused a
decrease in expression. The type VIII response is con-
sistent with a model whereby constitutive expression is
repressed and exogenous ligand also causes repression
through mechanisms described above for type I and IV
response types.
There are several possible explanations for the lack of
detecting PPARβ/δ occupancy near the TSS of the differ-
ent response type genes. It is possible that PPARβ/δ reg-
ulates these genes in regions further away than ± 10 kb
from the TSS, or that regulation is mediated by another
direct PPARβ/δ target gene that in turn directly regu-
lates the target genes. This mechanism is likely for the
type VII response gene because promoter occupancy
of PPARβ/δ was not detected within 10 kb of the TSS.
Alternatively, PPARβ/δ could occupy the regulatory
regions of the response genes, but the ChIP may not be
sensitive enough to effectively pull down chromatin with
bound PPARβ/δ, which could be influenced by the rela-
tive ability of the antibody to bind with PPARβ/δ. The
relative antibody binding to PPARβ/δ occupying chro-
matin could be impaired if: 1) conformational changes
resulting from different co-effector molecules bound to
PPARβ/δ are present, limiting access of the receptor to
the antibody, 2) PPARβ/δ is indirectly bound to chroma-
tin as part of a larger regulatory complex, 3) proteins are
bound to PPARβ/δ as a result of the crosslinking step of
the ChIP, and/or 4) the residence time of PPARβ/δ is too
brief to register a signal in the ChIP-seq analysis because
the receptor is rapidly exchanging with chromatin as
observed with many other receptors [15-18].
PPARβ/δ target genes were recently identified from
microarray analysis of human myofibroblast-like cells
following either siRNA knockdown of PPARβ/δ or lig-
and activation of PPARβ/δ in these cells [13]. Adhikary
and colleagues identified 595 genes that were regulated
by a PPARβ/δ ligand in human WPMY1 cells [13],
whereas only 130 genes were specifically regulated by
ligand activation of PPARβ/δ in mouse keratinocytes in
the present study (Additional file 3: Table S4). Of the
130 genes that were regulated by ligand activation of
PPARβ/δ in mouse keratinocytes, 24 (19%, Additional
file 4: Table S5) were also regulated by ligand activation
of PPARβ/δ in human WPMY1 cells [13]. Adhikary and
colleagues also identified 3704 genes that were regulated
following knockdown of PPARβ/δ in human WPMY1
cells [13]. In contrast, 482 genes were differentially regu-
lated in the absence of PPARβ/δ expression in mouse
keratinocytes in the present study. Of the 482 genes that
were differentially regulated by PPARβ/δ in mouse kera-
tinocytes as detected by comparing wild-type and
Pparβ/δ-null cells, 79 (16%, Additional file 4: Table S5)
were also regulated by disrupting expression of PPARβ/δ
in human WPMY1 cells [13]. Thus, of the 612 genes
that were regulated by PPARβ/δ in mouse primary kera-
tinocytes, 103 of these genes were also regulated by
PPARβ/δ in WPMY1 cells (Additional file 4: Table S5).
For approximately 50% of these genes, the response type
exhibited was identical between mouse primary kerati-
nocytes and WPMY1 cells (Additional file 4: Table S5).
Many interchanges of response types were observed
between the remaining genes but interchanges from
type II to type I, type III to type I, and type I to type II
were slightly more commonly noted in mouse primary
keratinocytes as compared to WPMY1 cell (Additional
file 4: Table S5). Collectively, these observations demon-
strate that PPARβ/δ regulates some common sets of
genes in human and mouse cells, but that there can also
be differences in the molecular targets and the types
of regulation observed. These differences might be due
to the presence or absence of one or more endogenous
ligand, differences in accessibility to regulatory regions
of chromatin, species differences in the sequences of bind-
ing motifs, differences in the approach used to delete/
knockdown PPARβ/δ (e.g. genetic versus siRNA), and/or
possible species differences in the expression levels of the
three PPARs between the two cell types.
The present studies identified eight different, PPARβ/
δ-dependent response types of genes in mouse keratino-
cytes. In contrast, others characterized only three differ-
ent PPARβ/δ-dependent response types in human
WPMY1 cells [13]. To facilitate comparisons with the
present study, data from Adhikary [13] was re-examined
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and indeed, all eight different response types were evi-
dent in these data. In mouse keratinocytes, constitutive
expression of 482 (79%) target genes was regulated by
PPARβ/δ through type I and II responses. In human
WPMY1 cells, 2728 genes (84%) were also regulated
through either a type I or type II response [13]. Type III
and IV responses observed following activation of
PPARβ/δ with an exogenous ligand were observed for
99 genes (16%) in mouse keratinocytes while 345 target
genes (11%) were regulated by similar mechanisms in
human WPMY1 cells [13]. Lastly, types V-VIII responses
were observed for 31 genes (11%) in mouse keratino-
cytes, whereas 186 genes (6%) were modulated similarly
in WPMY1 cells [13]. These data suggest that regulation
of gene expression in mouse keratinocytes and human
WPMY1 cells is likely mediated in large part by the
one or more endogenous ligand, and that activation of
PPARβ/δ with an exogenous ligand modulates expres-
sion of a relatively smaller set of genes as compared to
those that are regulated by PPARβ/δ endogenously.
ChIP-seq analysis revealed new insight into the func-
tional role of PPARβ/δ in the regulation of gene expres-
sion in keratinocytes. PPARβ/δ is constitutively enriched
on chromatin on chromosomes 7, 9, 11 and 17, and in
response to exogenous ligand activation, PPARβ/δ is
enriched on chromatin located on chromosomes 2, 4,
7 and 11. These findings indicate an important role for
PPARβ/δ in regulating genes encoded on these chromo-
somes. Interestingly, while ChIP-seq demonstrated that
PPARβ/δ was present near ~6700 genes in the mouse
genome, only 203 of these genes were regulated by
PPARβ/δ when compared with microarray analysis. This
is likely due in part to the presence of PPARβ/δ in in-
tronic sequences that may or may not be functional.
One mechanism that might explain the occupancy of
PPARβ/δ on chromatin not associated with genes that
were found to be regulated based on microarray analysis
is that PPARβ/δ may require the presence of other tran-
scription factors or signaling molecules in order to
modulate gene expression. For example, the aryl hydro-
carbon receptor (AHR) occupies the interleukin 6 (IL6)
promoter but does not modulate expression of IL6 un-
less NF-kB becomes activated through IL1β-dependent
signaling [44]. This type of signaling paradigm has not
been examined to date for PPARβ/δ, and results from
the present studies suggest this possibility could exist
and should be examined in future studies. This sug-
gests that while 612 genes were regulated specifically
by PPARβ/δ, many of these changes appear to be
mediated by mechanisms that are secondary to effects
induced by the direct target genes. Alternatively, it
remains possible that there are more direct target
genes, but the regulatory elements are more distal
than ± 10 kb from TSS.
ChIP-seq analysis provided a unique opportunity to
begin to examine the molecular mechanisms by which
PPARβ/δ differentially regulates gene expression. A con-
sensus PPRE was derived from these analyses and was
comparable to PPREs identified for other PPARβ/δ tar-
get genes [13,29]. No consistent differences in the PPRE
sequences were identified that were able to distinguish
between the different response types. However, the pres-
ence of binding site motifs for other transcription factors
was observed that distinguished between effects observed
with and without exogenous ligand. For example, the
ETS binding sites were commonly present near the PPRE
of genes that were modulated in the presence or absence
of exogenous ligand, whereas the CREB/ATF/AP1 bind-
ing sites were commonly present near the PPRE of genes
that were modulated only in the presence of exogenous
ligand. Interestingly, different patterns of consensus
binding sites of various transcription factors were also
noted near the PPRE of genes that exhibited types I, II
and III responses, but not for the other five response
types. Of particular interest, is the novel finding that
PPARβ/δ cooperates with ATF4 in modulating expres-
sion of some target genes. This suggests that PPARβ/δ
requires cooperation with other transcription factors
to specifically regulate subsets of genes. A similar
phenomenon has also been found for other transcription
factors [45-47]. While the physiological role of ATF4 in
modulating PPARβ/δ-dependent gene expression and
function requires further investigation, this type of inter-
action might begin to explain some of the complex regu-
lation associated with the dynamic and fluid nature of
nuclear receptor binding with chromatin.
Conclusions
Keratinocytes express high levels of PPARβ/δ and thus
provide an ideal model to study the role of this tran-
scription factor in gene expression. Comparisons of gene
expression profiles between wild-type and Pparβ/δ-null
keratinocytes treated with and without a highly specific
ligand identified 612 genes that were modulated either
constitutively or by the addition of an exogenous ligand.
Many of these changes in gene expression appear to
be modulated by the presence of an endogenous ligand
because expression is altered when PPARβ/δ is genetic-
ally silenced. ChIP-seq analysis revealed that only 203 of
these 612 genes exhibit direct binding of PPARβ/δ
within ± 10 Kb of the TSS. This suggests that: 1)
PPARβ/δ may indirectly regulate some of the 612 genes,
2) the dynamic nature of PPARβ/δ binding and interact-
ing with chromatin prevents detection of receptor occu-
pancy by ChIP-seq, and/or 3) PPARβ/δ may directly
regulate these genes by binding with chromatin at more
distant sites. The diversity in response types detected
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from this analysis supports a model of PPARβ/δ interact-
ing with chromatin through dynamic binding and inter-
actions; differences in receptor activity induced by
endogenous versus exogenous ligands may explain part
of this diversity. The presence of additional transcription
factors can influence the activity of PPARβ/δ in kerati-
nocytes. Interestingly, there can be considerable overlap
in target genes and response types observed between
human and mouse cells.
Methods
Chemicals
GW0742 was kindly provided by Drs. Andrew Billin and
Timothy Willson.
Isolation and culture of mouse keratinocytes
Animal experiments were approved by the Institutional
Animal Care and Use Committee at The Pennsylvania
State University, which conforms to the Guide for the
Care and Use of Laboratory Animals published by the
National Institutes of Health. Keratinocytes were isol-
ated from newborn mouse skin from wild-type or
Pparβ/δ-null mice [35], and cultured as previously
described [32,48]. Keratinocytes were cultured until
~80% confluent and then treated with 1 μM GW0742 or
vehicle control (dimethylsulfoxide) for up to twenty-four
hours and then used to isolated chromatin or RNA.
Microarray analysis
Total RNA was isolated from wild-type or Pparβ/δ-null
keratinocytes, treated with or without GW0742 for
twenty-four hours, using TRIZOL reagent (Invitrogen,
Carlsbad, CA) and purified with an RNeasy Mini Kit
(Qiagen, Valencia, CA). One hundred nanograms of
total RNA per sample was prepared for analysis with the
GeneChip Mouse Gene 1.0 ST Array (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions.
The Robust Multichip Average (RMA) approach was
used for normalization of microarray data using the R/
Bioconductor package as previously described [49]. To
identify genes that were significantly regulated by
PPARβ/δ or GW0742, a false discovery rate (FDR) cut-
off of 0.25 and a fold-change of 1.3 were used. The
DAVID algorithm was used to functionally categorize
genes involved in different biological process as previ-
ously described [27]. Data have been deposited in NCBI’s
Gene Expression Omnibus (GEO) database (http://www.
ncbi.nlm.nih.gov/geo) and are accessible through GEO
Series accession number GSE32498.
Quantitative realtime polymerase chain reaction (qPCR)
Total RNA was isolated from wild-type or Pparβ/δ-null
keratinocytes, treated with or without GW0742 for
twenty-four hours as described above. qPCR was
performed as previously described [50] using different
primer sets (Additional file 5: Table S1).
Chromatin immunoprecipitation (ChIP)
The ChIP-IT Express kit (Active Motif, Carlsbad, CA)
was used to isolate chromatin for ChIP. Mouse primary
keratinocytes were treated with or without 0.2 μM
GW0742 for four hours. Cells were then treated with 1%
formaldehyde for 10 min followed by glycine stop solu-
tion (125 mM) for 5 minutes. Cells were washed twice
with ice-cold phosphate buffered saline, collected by
scraping, and then centrifuged for 10 minutes at
2,500 rpm at 4°C. Cells were then snap frozen and
stored at −80°C. Frozen cell pellets were resuspended in
ice-cold lysis buffer (50 mM Tris–HCl, pH 8, 1% SDS,
10 mM EDTA, and protease inhibitor cocktail) and incu-
bated at 4°C for 30 minutes, then homogenized with
10 strokes in a Dounce homogenizer. Nuclei were
collected by centrifugation for 10 minutes at 2,500 rpm
at 4°C then resuspended in ice-cold shearing buffer and
incubated on ice for 10 minutes. Shearing was per-
formed by sonication using 30-second pulses in a Diage-
node Bioruptor (Diagenode, Sparta, NJ) to produce
fragments ranging in size from 300-500 bp. Forty micro-
grams of DNA was used per immunoprecipitation (IP),
or four micrograms per 10% input. Each IP was per-
formed overnight at 4°C in a reaction mixture compris-
ing sheared chromatin, protein G magnetic beads, and
either: 1) an anti-acetylated histone 4 (Upstate Biotech-
nology, Lake Placid, NY); 2) an anti-PPARβ/δ antibody
8099 [2], an anti-ATF4 (Santa Cruz Biotechnology, Santa
Cruz, CA) or 4) rabbit or goat IgG (Santa Cruz Biotech-
nology, Santa Cruz, CA). Following centrifugation, wash-
ing, and elution, the samples were reverse cross-linked
by overnight incubation at 65°C and treated with pro-
teinase K. Quantitative polymerase chain reactions
(qPCR) were performed to amplify an intronic PPRE re-
gion of the Angptl4 gene or the Adrp gene as previously
described [20,51]. To validate putative binding regions
proximal to target genes, ChIP assays were performed
as described above using primers designed to amplify
regions encoding between 75 and 300 bp (Additional
file 5: Table S1).
ChIP-seq
ChIP-seq was performed twice with the same samples to
obtain between 15,000,000 and 23,000,00 sequence reads
of ~36 base pairs per sample using the Illumina Genome
Analyzer at the National Cancer Institute, Center for
Cancer Research Sequencing Facility. The sequence
reads were quality filtered and mapped to the mouse
genome (Mus musculus, mm9 assembly, [52]) using
Bowtie [53] with the following settings (−n 2 –e 70 –m
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−1-k 1). Aligned results from both sequencing runs
were combined.
Peak calling
Regions of local enrichment of 36-mer short-read tags
were identified using a peak calling algorithm essentially
as described previously [54]. Input samples were nor-
malized to match the number of tags in the correspond-
ing ChIP data. Enrichment of tags within a 150 bp target
window after subtraction of normalized input tags was
gauged relative to a 200 kb background window using a
binomial distribution model. Each tag window was
assigned a probability p given by the ratio (# of uniquely
mappable base pairs in the 150 bp window)/(# of
uniquely mappable base pairs for the 200 kb window).
The overall z-score for the observed number of tags in the
target window was defined by z = (n – μ)/σ, where σ was
the standard deviation, μ was the expected number of tags
overlapping the target window, with n and N observed
tags overlapping the target window and background win-
dow, respectively. A putative peak was defined as a 150 bp
window whose peak z-score was >60. Peaks overlapping
by >1 bp with non-specific peaks identified in knockout
ChIP samples were excluded. Finally, the filtered peaks for
wild-type ± GW0742 were mapped to their nearest tran-
scriptional start sites and intersected with differentially
regulated genes identified from expression profiling (see
below) to yield the final target gene sets.
Transcriptional profiling and response type determination
Probe names were mapped to gene names using the
manufacturer’s provided annotations for the Affymetrix
Mouse Gene 1.0 ST Array. Differentially regulated genes
were categorized into eight response types according
to patterns of repression or induction by ligand and/or
receptor deletion using a fold-change threshold of ± 1.3
and an FDR cutoff of 0.25.
Identification of DNA binding motifs
To identify consensus peroxisome proliferator response
element (PPRE) motifs for PPARβ/δ in the binding
region set, the loci associated with each peak loci were
expanded to yield 400 bp regions for motif searching. A
list of 53 validated PPRE consensus sequences obtained
from the literature [29] were used to produce a TRANS-
FAC matrix representing the known DR1 PPRE motif
[30]. The ‘Screen Motif ’ tool in the Cistrome platform
was used to identify sequences within the 400 bp peak
regions matching this consensus motif, or the half site
(M01282) [55]. The ‘SeqPos’ tool was used to identify
additional motifs statistically enriched within the 400 bp
peak regions by searching the curated cistrome motif
database encompassing the TRANSFAC, JASPAR, uniP-
ROBE, and hPDI motif databases [56]. The same
analyses were performed on 400 bp peak regions identi-
fied in Pparβ/δ-null samples, and motifs enriched in
both wild-type and Pparβ/δ-null sample regions were
omitted to correct for background. Related motifs were
identified using the Phylogeny Inference Package (PHY-
LIP) via STAMP [30,57], and the Newick-format tree
plotted using MEGA [58].
Functional category enrichment
Gene ontology analysis was performed using DAVID to
identify the PANTHER functional gene categories
enriched within the eight response types using the official
gene names as identifiers [27,59,60]. A P value cutoff of
0.05 was applied after the Benjamini-Hochberg procedure
for correction of multiple hypothesis testing [27,59].
ATF4 knockdown and characterization of gene expression
Knockdown of ATF4 in SP1 cells was achieved by infect-
ing cells using the manufacturer’s recommended pro-
tocol with lentiviral shRNA vectors (Sigma-Aldrich,
St. Louis. MO) encoding the following four sequences:
1) Atf4 shRNA1: 50–CCGGGCGAGTGTAAGGAGC
TAGAAACTCGAGTTTCTAGCTCCTTACATTCGC
TTTTTG–30; 2) Atf4 shRNA2: 50–CCGGCCAGAG
CATTCCTTTAGTTTACTCGAGTAAACTAAAGGA
ATGCTCTGGTTTTTG–30; 3) Atf4 shRNA3: 50–CCG
GCCTCTAGTCCAAGAGACTAATCTCGAGATTAG
TCTCTTGGACTAGAGGTTTTTG–30; 4) control shRNA
50–CCGGCAACAAGATGAAGAGCACCAACTCGAG
TTGGTGCTCTTCATCTTGTTGTTTTT–30. Cells were
infected with vectors for 48 hours before selection with
puromycin for another 48 hours. Puromycin-resistant
SP1 cells were subcultured and treated with or without
GW0742 (1 μM) for 24 hours, before isolation of mRNA
or protein. qPCR analysis and quantitative western blots
were performed as previously described [50].
Additional files
Additional file 1: Table S2. 612 PPARβ/δ-dependent genes sorted by
response type.
Additional file 2: Table S3. 203 direct PPARβ/δ target genes sorted by
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